NEWS

How R&D and Manufacturing Leaders Can Prepare Now As we move toward 2026, the pharmaceutical and biotech landscape is shaped by rapid innovation, changing supply needs, and increasing pressure to deliver programs more efficiently. Organizations that understand these shifts early will be positioned to advance development timelines, reduce risk, and strengthen their competitive advantage. At DDA, we follow these trends closely to support our clients with informed and strategic

Chemistry, Manufacturing, and Controls (CMC) activities are central to every successful drug development program. Each step, from raw material sourcing to analytical validation, influences quality, cost, and speed to market. Partnering with an experienced CMC consultant through Drug Discovery Alliances (DDA) provides access to specialized expertise and a global network designed to help programs progress efficiently and compliantly. Below are ten reasons why working with DDA c

Artificial intelligence has transformed nearly every corner of the pharmaceutical industry, from predictive modeling and automated screening to generative chemistry. Yet even with its accelerating influence, there are critical aspects of drug development that will never be replaced. At  Drug Discovery Alliances , we view AI as a powerful enabler of innovation, not a replacement for the expertise, judgment, and collaboration that truly drive pharmaceutical progress. 1. Scienti

In the fast-paced world of life sciences, the success of an R&D program relies on more than just innovative science. It requires a...